Partner Janet Xiao offers optimism for cross-border deals in 2018 in the BioWorld article “‘Spirit’ of JPM lives on as other meetings muscle in on biopharma playground.”
“Biopharma is definitely the forerunner in terms of cross-border dealmaking,” she said, serving as a moderator at the Chinese American Biopharmaceutical Society (CABS) Investor Forum. Last year set a record for U.S.-China cross-border transactions in biopharma, she said, with assets in oncology and I-O, cell therapy and cardiovascular disease at the top of their prospect list, along with drug and device treatments for diabetes.
Ms. Xiao continued to say that investors in China have grown more sophisticated about evaluating technologies that fill gaps in their internal development, “so the deals they're looking for have become more tailored to their specific needs.”
Read the full article.